Targeting NF-κB Signaling for Multiple Myeloma
Ada Hang‐Heng Wong, Eun Myoung Shin, Vinay Tergaonkar, Wee Joo Chng
Abstract
Multiple myeloma (MM) is the second most common hematologic malignancy in the world. Even though survival rates have significantly risen over the past years, MM remains incurable, and is also far from reaching the point of being managed as a chronic disease. This paper reviews the evolution of MM therapies, focusing on anti-MM drugs that target the molecular mechanisms of nuclear factor kappa B (NF-κB) signaling. We also provide our perspectives on contemporary research findings and insights for future drug development.
Topics & Concepts
Multiple myelomaHematologic malignancyMalignancyMedicineDrug developmentDiseaseNFKB1Cancer researchOncologyBioinformaticsInternal medicineDrugPharmacologyBiologyTranscription factorGeneGeneticsMultiple Myeloma Research and TreatmentsProtein Degradation and InhibitorsPeptidase Inhibition and Analysis